J
Jan Budczies
Researcher at University Hospital Heidelberg
Publications - 185
Citations - 16222
Jan Budczies is an academic researcher from University Hospital Heidelberg. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 48, co-authored 166 publications receiving 12762 citations. Previous affiliations of Jan Budczies include German Cancer Research Center & Humboldt University of Berlin.
Papers
More filters
Journal ArticleDOI
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.
Balazs Gyorffy,András Lánczky,Aron Charles Eklund,Carsten Denkert,Jan Budczies,Qiyuan Li,Zoltan Szallasi,Zoltan Szallasi +7 more
TL;DR: An online tool to draw survival plots, which can be used to assess the relevance of the expression levels of various genes on the clinical outcome both in untreated and treated breast cancer patients, and which validated the capability of microarrays to determine estrogen receptor status in 1,231 patients.
Journal ArticleDOI
Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer
TL;DR: An integrated database and an online tool capable of uni- and multivariate analysis for in silico validation of new biomarker candidates in non-small cell lung cancer are established.
Journal ArticleDOI
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert,Sibylle Loibl,Aurelia Noske,Marc Roller,Berit Maria Müller,Martina Komor,Jan Budczies,Silvia Darb-Esfahani,Ralf Kronenwett,Claus Hanusch,Christian von Törne,Wilko Weichert,Knut Engels,Christine Solbach,Iris Schrader,Manfred Dietel,Gunter von Minckwitz +16 more
TL;DR: The presence of tumor-associated lymphocytes in breast cancer is a new independent predictor of response to anthracycline/taxane neoadjuvant chemotherapy and provides useful information for oncologists to identify a subgroup of patients with a high benefit from this type of chemotherapy.
Journal ArticleDOI
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert,Gunter von Minckwitz,Silvia Darb-Esfahani,Bianca Lederer,Barbara Ingold Heppner,Karsten Weber,Jan Budczies,Jens Huober,Frederick Klauschen,Jenny Furlanetto,Wolfgang D. Schmitt,Jens-Uwe Blohmer,Thomas Karn,Berit M. Pfitzner,Sherko Kümmel,Knut Engels,Andreas Schneeweiss,Arndt Hartmann,Aurelia Noske,Peter A. Fasching,Christian Jackisch,Marion van Mackelenbergh,Peter Sinn,Christian Schem,Claus Hanusch,Michael Untch,Sibylle Loibl +26 more
TL;DR: The hypothesis that breast cancer is immunogenic and might be targetable by immune-modulating therapies is supported and increased TIL concentration predicted response to neoadjuvant chemotherapy in all molecular subtypes assessed.
Journal ArticleDOI
Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization
Jan Budczies,Frederick Klauschen,Bruno Valentin Sinn,Balázs Győrffy,Wolfgang D. Schmitt,Silvia Darb-Esfahani,Carsten Denkert +6 more
TL;DR: The functionality of Cutoff Finder is illustrated by the analysis of the gene expression of estrogen receptor and progesterone receptor in breast cancer tissues, which is analyzed and correlated with immunohistologically determined ER status and distant metastasis free survival.